A Study to Determine the Performance of the Press Fit Condylar (P.F.C.) Sigma RP-F Knee System - Full Text View

Purpose

The purpose of this study is to evaluate if the P.F.C. Sigma RPF knee accommodates functional stability with a post-operative passive range of motion of greater than 125° of flexion and to demonstrate that the range of motion does not compromise the longevity of the implant.

Condition	Intervention	Phase
Osteoarthritis	Device: P.F.C. Sigma RP-F Total Knee Replacement	Phase 4

Study Type:	Interventional
Study Design:	Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Prospective, Non-Comparative Multi Centre Study to Evaluate the Clinical Performance of the DePuy Press Fit Condylar (P.F.C.) Sigma Rotating Platform High Flexion Knee.

Resource links provided by NLM:

MedlinePlus related topics: Knee Replacement Osteoarthritis

U.S. FDA Resources

Further study details as provided by DePuy International:

Primary Outcome Measures:

90% of patients have a functionally stable knee that can achieve post-operative range of motion of 125° or greater. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

The first secondary endpoint is to investigate the survivorship of the P.F.C.® Sigma RPF knee at 1, 2, 3, 5, 10, 15 and 20 years. [ Time Frame: 1,2, 3 and 5 years ] [ Designated as safety issue: No ]

Enrollment:	180
Study Start Date:	October 2004
Estimated Study Completion Date:	January 2029
Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
P.F.C. Sigma RP-F Total Knee Replacement An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design	Device: P.F.C. Sigma RP-F Total Knee Replacement An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design

Detailed Description:

Primary endpoint is to demonstrate that 90% of patients have a functionally stable knee that can achieve post operative range of motion of 125 degrees or greater.

The secondary endpoint is to investigate the survivorship of the P.F.C. Sigma RP-F knee at 1, 2, 3, 5, 10, 15 and 20 years

Eligibility

Ages Eligible for Study:	45 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female subjects, aged between 45 and 75 years inclusive.
Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.
Subjects who are able to achieve a pre-operative passive range of motion of equal to or greater than 125º.
Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
Subjects who present with idiopathic osteoarthritis that in the opinion of the clinical investigator requires a primary total knee arthroplasty.
Subjects who in the opinion of the Clinical Investigator are considered to be suitable for treatment with the P.F.C.â Sigma RPF knee, according to the indications specified in the package insert leaflet.

Exclusion Criteria:

Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
Women who are pregnant.
Subjects who are known drug or alcohol abusers or with psychological disorders that could effect follow-up care or treatment outcomes.
Subjects who have participated in a clinical study with an investigational product in the last month (30 days).
Subjects who are currently involved in any personal injury litigation claims.
Subjects with a known history of poor compliance to medical treatment.
Subjects who have a pre-operative limb deformity of equal to or greater than 10° varus or 15° valgus as defined using the anatomical axis.
Subjects who have morbid obesity i.e. BMI ≥40.
Subjects who wish to have a simultaneous bilateral procedure. However, subjects who have had a staged bilateral procedure may be included as long as the previous procedure was performed 9 or more months prior to their inclusion in the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00761410

Locations

India
The Nook, 51/B SV Road
Mumbai, Maharashtra, India, 400 054
Japan
Kobe University Graduate School Of Medicine, 7-5-1 Kusundki- cho
Chuoku, Kobe, Japan
Korea, Republic of
Kyunghee University Hospital, 1 HoegiDong
Dongdaemun Gu, Seoul, Korea, Republic of
New Zealand
Wellington School Of Medicine Surgical Research Trust, Main Street
Newtown, Wellington, New Zealand
Singapore
Tan Tock Seng Hospital, No 11 Jalan
Tan Tock Seng, Singapore, 308433
Thailand
Sirriraj Hospital, Mahidol University
Bangkok, Thailand, 10700
United Kingdom
Nottingham City Hospital, Hucknell Road
Nottingham, United Kingdom, NG5 1PB
Clifton Park NHS Treatment Centre, Blue Beck Drive, Shipton Road
York, United Kingdom

Sponsors and Collaborators

DePuy International

Investigators

Principal Investigator:

Rajesh Maniar, FRCS

The Nook, 51/B SV Road, Mumbai, Maharashtra, India

More Information

No publications provided

Responsible Party:	DePuy International
ClinicalTrials.gov Identifier:	NCT00761410 History of Changes
Other Study ID Numbers:	CT0153
Study First Received:	September 26, 2008
Last Updated:	September 11, 2012
Health Authority:	United Kingdom: Research Ethics Committee

Keywords provided by DePuy International:

Arthroplasty
Knee
Replacement
High Flexion
PFC Sigma RP-F

Additional relevant MeSH terms:

Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on May 16, 2013